News
-
Viatris announced that it has acquired Aculys Pharma, which in 2022 had acquired development and commercialization rights to Neurelis’s NRL-1 (Valtoco) intranasal diazepam for the treatment of epilepsy in Japan, Australia, and other Asia-Pacific countries. In… Read more . . .
-
US-based biotech Eradivir announced that a Phase 1/2a trial of its EV25 intranasal antiviral for the treatment of influenza demonstrated that a single 300 mg dose resulted in a significant reduction in lower respiratory tract… Read more . . .
-
The FDA has granted 510(k) clearance to Aptar Digital Health’s HeroTracker Sense MDI sensor, the company said. Aptar acquired the sensor’s developer, Cohero Health, in 2020 and launched the Bluetooth-enabled sensor in 2022. According to the… Read more . . .
-
According to Chiesi, the FDA has accepted the company’s NDA for its CHF5993 beclomethasone dipropionate /formoterol fumarate / glycopyrrolate MDI for the treatment of asthma. In April 2024, Chiesi announced that it was initiating a… Read more . . .
-
MannKind Corporation announced that the FDA has accepted the company’s sBLA for the use of Afrezza inhaled dry powder insulin in diabetes patients aged 4 to 17 and has set a PDUFA date of May 29, 2026.… Read more . . .
-
German CDMO LTS Lohmann has announced that it will acquire US-based CDMO Renaissance Lakewood, which specializes in injectables and nasal sprays. According to the announcement, Renaissance currently employs approximately 500 employees. LTS currently offers services for… Read more . . .
-
Inhalation CDMO Bespak has announced the appointment of former automotive industry executive Tarik Hage as Chief Commercial Officer. Hage was most recently VP of Commercial and Business Development at GKN Automotive, where he had worked… Read more . . .
-
Chance Pharmaceuticals has announced a new agreement giving Huadong Medicine the rights to commercialize Chance Pharma’s CXG87 formoterol / budesonide DPI in mainland China. Financial details of the agreement were not disclosed. In March 2025,… Read more . . .
-
Nasus Pharma announced that it has signed a deal with Aptar for the use of Aptar’s Unit Dose System (UDS) nasal powder delivery device for Nasus’ NS002 (formerly FMXIN002) intranasal dry powder epinephrine product candidate… Read more . . .
-
Lupin has announced that it will invest $250 million over 5 years to build a new 70,000 sq ft inhaler manufacturing facility in Coral Springs, Florida, USA, where the company opened an inhalation research center… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK